![Pharmaceutics | Free Full-Text | Anti-Psoriasis Effect of Diclofenac and Celecoxib Using the Tail Model for Psoriasis Pharmaceutics | Free Full-Text | Anti-Psoriasis Effect of Diclofenac and Celecoxib Using the Tail Model for Psoriasis](https://www.mdpi.com/pharmaceutics/pharmaceutics-14-00885/article_deploy/html/images/pharmaceutics-14-00885-g004.png)
Pharmaceutics | Free Full-Text | Anti-Psoriasis Effect of Diclofenac and Celecoxib Using the Tail Model for Psoriasis
![Celecoxib Versus Naproxen and Diclofenac in Osteoarthritis Patients: SUCCESS-I Study - ScienceDirect Celecoxib Versus Naproxen and Diclofenac in Osteoarthritis Patients: SUCCESS-I Study - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0002934305009137-gr2.jpg)
Celecoxib Versus Naproxen and Diclofenac in Osteoarthritis Patients: SUCCESS-I Study - ScienceDirect
![Lessons from 20 years with COX‐2 inhibitors: Importance of dose–response considerations and fair play in comparative trials - Stiller - 2022 - Journal of Internal Medicine - Wiley Online Library Lessons from 20 years with COX‐2 inhibitors: Importance of dose–response considerations and fair play in comparative trials - Stiller - 2022 - Journal of Internal Medicine - Wiley Online Library](https://onlinelibrary.wiley.com/cms/asset/21bff47b-52e2-4d1f-b271-23ecf9014267/joim13505-fig-0003-m.jpg)
Lessons from 20 years with COX‐2 inhibitors: Importance of dose–response considerations and fair play in comparative trials - Stiller - 2022 - Journal of Internal Medicine - Wiley Online Library
![Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison - The Lancet Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison - The Lancet](https://www.thelancet.com/cms/attachment/2000989387/2003643106/gr1.jpg)
Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison - The Lancet
![PDF) Celecoxib versus diclofenac for the treatment of ankylosing spondylitis: 12-week randomized study in Norwegian patients PDF) Celecoxib versus diclofenac for the treatment of ankylosing spondylitis: 12-week randomized study in Norwegian patients](https://www.researchgate.net/publication/298424480/figure/tbl1/AS:668937205342222@1536498466889/Changes-from-baseline-in-secondary-efficacy-endpoints-at-Week-12-in-Norwegian-patients_Q320.jpg)
PDF) Celecoxib versus diclofenac for the treatment of ankylosing spondylitis: 12-week randomized study in Norwegian patients
![Non-steroidal anti-inflammatory drugs: recent advances in the use of synthetic COX-2 inhibitors - RSC Medicinal Chemistry (RSC Publishing) DOI:10.1039/D1MD00280E Non-steroidal anti-inflammatory drugs: recent advances in the use of synthetic COX-2 inhibitors - RSC Medicinal Chemistry (RSC Publishing) DOI:10.1039/D1MD00280E](https://pubs.rsc.org/image/article/2022/MD/d1md00280e/d1md00280e-f5_hi-res.gif)
Non-steroidal anti-inflammatory drugs: recent advances in the use of synthetic COX-2 inhibitors - RSC Medicinal Chemistry (RSC Publishing) DOI:10.1039/D1MD00280E
![Comparison of two different dosages of celecoxib with diclofenac for the treatment of active ankylosing spondylitis: results of a 12-week randomised, double-blind, controlled study | Annals of the Rheumatic Diseases Comparison of two different dosages of celecoxib with diclofenac for the treatment of active ankylosing spondylitis: results of a 12-week randomised, double-blind, controlled study | Annals of the Rheumatic Diseases](https://ard.bmj.com/content/annrheumdis/67/3/323/F1.large.jpg)
Comparison of two different dosages of celecoxib with diclofenac for the treatment of active ankylosing spondylitis: results of a 12-week randomised, double-blind, controlled study | Annals of the Rheumatic Diseases
![Gastrointestinal safety of celecoxib versus naproxen in patients with cardiothrombotic diseases and arthritis after upper gastrointestinal bleeding (CONCERN): an industry-independent, double-blind, double-dummy, randomised trial - The Lancet Gastrointestinal safety of celecoxib versus naproxen in patients with cardiothrombotic diseases and arthritis after upper gastrointestinal bleeding (CONCERN): an industry-independent, double-blind, double-dummy, randomised trial - The Lancet](https://www.thelancet.com/cms/attachment/f897a86b-51ec-469d-937e-c1560a13fb9b/gr1.gif)
Gastrointestinal safety of celecoxib versus naproxen in patients with cardiothrombotic diseases and arthritis after upper gastrointestinal bleeding (CONCERN): an industry-independent, double-blind, double-dummy, randomised trial - The Lancet
![Celecoxib versus Diclofenac and Omeprazole in Reducing the Risk of Recurrent Ulcer Bleeding in Patients with Arthritis | NEJM Celecoxib versus Diclofenac and Omeprazole in Reducing the Risk of Recurrent Ulcer Bleeding in Patients with Arthritis | NEJM](https://www.nejm.org/na101/home/literatum/publisher/mms/journals/content/nejm/2002/nejm_2002.347.issue-26/nejmoa021907/production/images/img_small/nejmoa021907_f1.jpeg)
Celecoxib versus Diclofenac and Omeprazole in Reducing the Risk of Recurrent Ulcer Bleeding in Patients with Arthritis | NEJM
![PDF) Celecoxib vs diclofenac sodium in patients with knee osteoarthritis: A protocol for systematic review and meta analysis PDF) Celecoxib vs diclofenac sodium in patients with knee osteoarthritis: A protocol for systematic review and meta analysis](https://www.researchgate.net/publication/340572126/figure/fig1/AS:903486816411648@1592419451532/Flow-diagram-of-study-selection_Q320.jpg)
PDF) Celecoxib vs diclofenac sodium in patients with knee osteoarthritis: A protocol for systematic review and meta analysis
![Comparative Inhibitory Activity of Etoricoxib, Celecoxib, and Diclofenac on COX‐2 Versus COX‐1 in Healthy Subjects - Schwartz - 2008 - The Journal of Clinical Pharmacology - Wiley Online Library Comparative Inhibitory Activity of Etoricoxib, Celecoxib, and Diclofenac on COX‐2 Versus COX‐1 in Healthy Subjects - Schwartz - 2008 - The Journal of Clinical Pharmacology - Wiley Online Library](https://accp1.onlinelibrary.wiley.com/cms/asset/322e3ee9-de8a-4b68-ae69-9d8c06c99539/jcph_745_f1.gif)
Comparative Inhibitory Activity of Etoricoxib, Celecoxib, and Diclofenac on COX‐2 Versus COX‐1 in Healthy Subjects - Schwartz - 2008 - The Journal of Clinical Pharmacology - Wiley Online Library
![Celecoxib versus diclofenac for the treatment of ankylosing spondylitis: 12-week randomized study in Norwegian patients - Chris Walker, Margaret N Essex, Chunming Li, Peter W Park, 2016 Celecoxib versus diclofenac for the treatment of ankylosing spondylitis: 12-week randomized study in Norwegian patients - Chris Walker, Margaret N Essex, Chunming Li, Peter W Park, 2016](https://journals.sagepub.com/cms/10.1177/0300060516628704/asset/images/large/10.1177_0300060516628704-fig1.jpeg)
Celecoxib versus diclofenac for the treatment of ankylosing spondylitis: 12-week randomized study in Norwegian patients - Chris Walker, Margaret N Essex, Chunming Li, Peter W Park, 2016
![Lessons from 20 years with COX‐2 inhibitors: Importance of dose–response considerations and fair play in comparative trials - Stiller - 2022 - Journal of Internal Medicine - Wiley Online Library Lessons from 20 years with COX‐2 inhibitors: Importance of dose–response considerations and fair play in comparative trials - Stiller - 2022 - Journal of Internal Medicine - Wiley Online Library](https://onlinelibrary.wiley.com/cms/asset/63c765d9-c539-4d2f-8fde-eb1a58bf13e8/joim13505-gra-0001-m.jpg)
Lessons from 20 years with COX‐2 inhibitors: Importance of dose–response considerations and fair play in comparative trials - Stiller - 2022 - Journal of Internal Medicine - Wiley Online Library
![Celecoxib versus Diclofenac and Omeprazole in Reducing the Risk of Recurrent Ulcer Bleeding in Patients with Arthritis | NEJM Celecoxib versus Diclofenac and Omeprazole in Reducing the Risk of Recurrent Ulcer Bleeding in Patients with Arthritis | NEJM](https://www.nejm.org/na101/home/literatum/publisher/mms/journals/content/nejm/2002/nejm_2002.347.issue-26/nejmoa021907/production/images/img_medium/nejmoa021907_t2.jpeg)